

FDA EXCLUSIVE: A Spotlight on Regulation in Antibacterial Drug Development

*FDA Division of Anti-Infective Products
Director, Sumathi Nambair, due to
Present at Superbugs & Superdrugs
2017*

LONDON, ENGLAND, UNITED KINGDOM, November 30, 2016 /EINPresswire.com/ -- SMi Group are thrilled to have industry expert Sumathi Nambair, provide regulatory and compliance updates on FDA legislation in antibacterial drug development at the 19th annual 2017 [Superbugs & Superdrugs](#) show, returning to Central London on 20th and 21st March.

The long running event will once again gather a global audience of scientific leaders, government bodies and anti-infective specialists, providing a focal point to discuss the global action plan on antimicrobial resistance.

In her current role at the FDA, Dr. Nambair provides regulatory oversight for anti-infective products, including antibacterial, antifungal, and antiparasitic drugs. Her [keynote presentation](#) will explore FDA development programmes and activities to facilitate antibiotic drug discovery.

SMi Group are also delighted to welcome the expertise of Xavier Duportet, CEO from Eligo Bioscience who has recently confirmed to speak. Following a €2M deal from leading microbiome investor, Seventure, the talk will offer progressive insight into sequence-specific antimicrobials for targeted eradication of carriage.



Networking and learning with our peers is the secret to improving the drug development pipeline.

*Joint statement from
Transcript Partners and
Chemical Biology Ventures*

The notable speaker line-up on at Superbugs & Superdrugs 2017 will also include:

Richard Bax, Senior Partner, TranScrip
Lloyd Czaplewski, Director, Chemical Biology Ventures
Chris Houchens, Branch Chief, BARDA

James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline
Aileen Rubio, Head of Biology, Spero Therapeutics



SMi's 19th Annual Event... SMi

Superbugs & Superdrugs

Copthorne Tara Hotel
London, UK

20TH - 21ST
MARCH
2017

www.superbugssuperdrugs.com

Superbugs and Superdrugs 2017

David Williams, Chief Executive Officer, Discuva
Martin Everett, Chief Scientific Officer, ANTABIO SAS
Jean de Gunzburg, Scientific Director, Da Volterra
William J Weiss, Director, Pre-Clinical Services, UNT System College of Pharmacy

For those looking to attend there is currently a £400 saving available online ending on 30th November 2017. More information is available online at www.superbugssuperdrugs.com

Superbugs & Superdrugs 2017
20TH & 21ST March
Cophthorne Tara Hotel, London, UK
<http://www.superbugssuperdrugs.com>

--end --

Contact Information:

For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
For delegate inquiries contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk
For exhibition and sponsorship inquiries contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri
SMi Group
2078276000
[email us here](mailto:teriarri@smi-online.co.uk)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.